Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 1/2 trial of its Vaxfectin genital herpes vaccine – a therapeutic inoculation that’s melded vaccine and DNA technologies. Here’s how it works: Vical’s approach directs the immune response in two ways: It teaches immune cells to develop weapons against the […]
Many companies are contending to hit the market first in the race for a genital herpes vaccine. The thread that ties them together? Immunotherapy – the wunderdrug for cancer therapy that’s now showing promise for infectious disease. But it hasn’t always been so, said Agenus CEO Garo Armen, whose immunotherapy approach in both cancer and in infectious disease […]
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.